Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Treasury Shares (2022 - 2025)

Historic Treasury Shares for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $724908.0.

  • NewAmsterdam Pharma's Treasury Shares rose 1907.57% to $724908.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $724908.0, marking a year-over-year increase of 1907.57%. This contributed to the annual value of $143002.0 for FY2024, which is 7651.0% down from last year.
  • Per NewAmsterdam Pharma's latest filing, its Treasury Shares stood at $724908.0 for Q3 2025, which was up 1907.57% from $718584.0 recorded in Q2 2025.
  • NewAmsterdam Pharma's Treasury Shares' 5-year high stood at $724908.0 during Q3 2025, with a 5-year trough of $143002.0 in Q4 2024.
  • Its 4-year average for Treasury Shares is $589611.7, with a median of $608779.0 in 2023.
  • As far as peak fluctuations go, NewAmsterdam Pharma's Treasury Shares plummeted by 7651.0% in 2024, and later soared by 1907.57% in 2025.
  • Quarter analysis of 4 years shows NewAmsterdam Pharma's Treasury Shares stood at $621105.1 in 2022, then fell by 1.98% to $608779.0 in 2023, then crashed by 76.51% to $143002.0 in 2024, then soared by 406.92% to $724908.0 in 2025.
  • Its Treasury Shares was $724908.0 in Q3 2025, compared to $718584.0 in Q2 2025 and $663790.0 in Q1 2025.